What is DNAHope?
DNAHope is a screening test for fetal chromosomal abnormalities in early pregnancy better known as Non-Invasive Prenatal Test (NIPT). The Non-Invasive Prenatal Test (NIPT) checks the number of chromosomes for which humans have 23 pairs of chromosomes, one of which is to determine the sex of your baby. The NIPT test can check the number of chromosomes, either to detect chromosome loss or chromosome duplication called aneuploidy. This phenomenon is often associated with mental or physical disabilities of varying severity.
Usually, the most common aneuploidy is trisomy 21 (Down syndrome), trisomy 18 (Edward's syndrome), trisomy 13 (Patau's syndrome) and abnormalities in the sex chromosomes (XXY, XYY, or XXX) or microdeletions which can all be known through DNAHope examination.
You can do DNAHope Twins as early as 10 weeks gestation at the doctor's office, in the laboratory, or even in your home in an easy way. This test uses a single blood draw sample from your arm as much as one tube of blood or about 8-10 cc. The report will be available within 14 working days. DNAnswer also provides follow-up services if the mother has a High Risk result, to perform amnionsentesis testing and genetic counseling.
Features of DNAHope Twins service:
1. Most frequent examination of chromosomes 21, 18, 13
2. Abnormalities in the sex chromosomes (XO, XXX, XXY, or XYY)
3. Gender check (optional, can be displayed or not shown)
4. Follow-up service if the test results show high risk (Karyotype)
Why Choose DNAHope?
HIGHLY ACCURATE Over 99% accuracy for detecting Down Syndrome, Edwards Syndrom, and Patau Syndrome.
PAINLESS AND SAFE Only 10 ml of blood from the mother required Unmatched safety for mother and developing fetus compared to current invasive testing methods
EARLY DETECTION AND BABY GENDER Test from as early as 10 gestational weeks and option to know your baby’s gender
PROTECTED Diagnos Genomics provides advanced diagnostic services for mothers with "High Risk" results.